Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levofloxacin-containing regimen for isoniazid-resistant tuberculosis
ACTRN12624000654550Phase 3Recruiting
- Sponsor
- The University of Sydney
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of levofloxacin, rifampicin, pyrazinamide and ethambutol in Tuberculosis (TB) and pulmonary tuberculosis (TB) (2 arms), sponsored by The University of Sydney. Primary endpoint: Sustained treatment success. Started Jun 2025; status: recruiting.
02
Drugs
levofloxacinrifampicinpyrazinamideethambutol
03
Conditions
Tuberculosis (TB)pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on ACTRN12624000654550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000654550.